moxifloxacin has been researched along with Pseudomonas Infections in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 5 (19.23) | 2.80 |
| Authors | Studies |
|---|---|
| Fernando, DM; Gorityala, BK; Goswami, S; Guchhait, G; Kumar, A; Schweizer, F; Zhanel, GG | 1 |
| Cevallos, AV; Keenan, JD; Lee, MD; Lin, YB; Oji, NM; Seitzman, GD | 1 |
| Bhamare, P; Dunman, PM; Johnson, W; Kinn, B; Laskey, E; Mei, JA; Nolin, L; Stalker, C; Wozniak, RAF | 1 |
| Berry, N; Byrne, DP; Fernig, DG; Foulkes, DM; Haneef, AS; Kaye, SB; McLean, K; Rustidge, S; Sloniecka, M; Winstanley, C | 1 |
| Cheng, L; Dai, Q; Ding, J; Feng, W; Li, X; Pu, W; Sun, F; Wang, J; Wang, Y; Yang, B; Yuan, Q; Zhang, D; Zhang, H | 1 |
| Galor, A; Huang, AM; Quan, AV | 1 |
| Graue-Hernandez, EO; Lichtinger, A; Navas, A; Polania-Baron, EJ; Santana-Cruz, O | 1 |
| Moussa, K; Schallhorn, JM; Shantha, J | 1 |
| Chojnacki, M; Dunman, PM; Philbrick, A; Reed, JN; Tomaras, A; Wozniak, RAF; Wucher, B | 1 |
| Acharya, NR; Borkar, DS; Fleiszig, SM; Ghanekar, AA; Lalitha, P; Leong, C; Li, WY; Lietman, TM; McLeod, SD; Srinivasan, M; Tam, C; Zegans, ME | 1 |
| Acharya, NR; Borkar, DS; Lalitha, P; Lietman, TM; Mascarenhas, J; McLeod, SD; Oldenburg, CE; Porco, TC; Rajaraman, R; Ravindran, M; Ray, KJ; Srinivasan, M; Zegans, ME | 1 |
| Buyck, JM; Peyrusson, F; Tulkens, PM; Van Bambeke, F | 1 |
| Akyar, I; Celik, E; Cosar, CB; Gonen, T; Ince, U; Kucuk, M; Serteser, M; Tokat, F | 1 |
| Galani, I; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kanellakopoulou, K; Sarafis, P | 1 |
| Hesje, CK; Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A | 1 |
| Acharya, NR; Glidden, D; Lalitha, P; Lietman, TM; Mascarenhas, J; McLeod, SD; Oldenburg, CE; Rajaraman, R; Ravindran, M; Ray, KJ; Srinivasan, M; Sy, A; Zegans, ME | 1 |
| Acharya, NR; Greninger, DA; Keenan, JD; Lietman, TM; Mascarenhas, J; McClintic, SM; Srinivasan, M | 1 |
| Acharya, NR; Geetha, M; Glidden, D; Karpagam, R; Lietman, TM; McLeod, SD; Oldenburg, CE; Prajna, L; Ray, KJ; Srinivasan, M; Sun, CQ | 1 |
| Bowker, KE; Holt, HA; MacGowan, AP; Rogers, CA | 1 |
| Elliott, MA; Patel, R; Prabhu, RM | 1 |
| Caballero, AR; Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA | 1 |
| Aliprandis, E; Ciralsky, J; Herling, I; Katz, HR; Lai, H | 1 |
| Marchese, A; Roveta, S; Schito, AM; Schito, GC | 1 |
| Feiz, V; Kang, PC; Mirzaian, G; Moshirfar, M | 1 |
| Asbell, PA; Bottone, EJ; Epstein, SP | 1 |
| RodrÃguez, JC; Royo, G; Ruiz, M; Sirvent, E | 1 |
3 trial(s) available for moxifloxacin and Pseudomonas Infections
| Article | Year |
|---|---|
Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India.
Topics: Anti-Bacterial Agents; Aza Compounds; Communicable Diseases, Emerging; Cornea; Corneal Ulcer; Double-Blind Method; Drug Resistance, Bacterial; Drug Therapy, Combination; Eye Infections, Bacterial; Fluoroquinolones; Glucocorticoids; Humans; India; Microbial Sensitivity Tests; Moxifloxacin; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2013 |
Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment.
Topics: Adult; Anti-Infective Agents; Aza Compounds; Corneal Ulcer; Double-Blind Method; Eye Infections, Bacterial; Female; Fluoroquinolones; Follow-Up Studies; Glucocorticoids; Humans; Male; Middle Aged; Moxifloxacin; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Treatment Outcome; Visual Acuity | 2012 |
Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Bacteria; Corneal Ulcer; Double-Blind Method; Drug Resistance, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Glucocorticoids; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Nocardia; Nocardia Infections; Pneumococcal Infections; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Streptococcus pneumoniae | 2013 |
23 other study(ies) available for moxifloxacin and Pseudomonas Infections
| Article | Year |
|---|---|
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2016 |
Assessment of Antimicrobial Activity of Dehydrated Amniotic Membrane in Infectious Keratitis: A Small Retrospective Case Series and In Vitro Study.
Topics: Acanthamoeba castellanii; Acanthamoeba Keratitis; Adolescent; Adult; Amnion; Anti-Bacterial Agents; Eye Infections, Bacterial; Humans; Keratitis; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pneumoniae | 2021 |
Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates.
Topics: Anti-Bacterial Agents; Bacitracin; Drug Combinations; Erythromycin; Framycetin; Humans; Keratitis; Levofloxacin; Moxifloxacin; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Tobramycin; Trimethoprim | 2022 |
Impact of fluoroquinolones and aminoglycosides on P. aeruginosa virulence factor production and cytotoxicity.
Topics: ADP Ribose Transferases; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; Ciprofloxacin; Fluoroquinolones; Genotype; Humans; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Virulence Factors | 2022 |
Targeted delivery of antibiotics to the infected pulmonary tissues using ROS-responsive nanoparticles.
Topics: A549 Cells; Animals; Anti-Bacterial Agents; Cyclodextrins; Delayed-Action Preparations; Drug Delivery Systems; Female; Humans; Lung; Mice; Moxifloxacin; Nanoparticles; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; RAW 264.7 Cells; Reactive Oxygen Species | 2019 |
Ciprofloxacin Corneal Deposits With Complete Dissipation After Switching to Moxifloxacin.
Topics: Administration, Ophthalmic; Aged; Anti-Bacterial Agents; Chemical Precipitation; Ciprofloxacin; Cornea; Corneal Ulcer; Drug Substitution; Eye Infections, Bacterial; Humans; Male; Moxifloxacin; Ophthalmic Solutions; Pseudomonas Infections; Slit Lamp Microscopy | 2020 |
Treatment of Severe Infectious Keratitis With Scleral Contact Lenses as a Reservoir of Moxifloxacin 0.5.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aspergillosis; Contact Lenses; Corneal Ulcer; Drug Carriers; Escherichia coli Infections; Eye Infections, Bacterial; Eye Infections, Fungal; Female; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Pseudomonas Infections; Sclera; Staphylococcal Infections; Visual Acuity; Young Adult | 2021 |
Blurry Vision and Eye Pain After Pterygium Surgery.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Eye Infections, Bacterial; Eye Pain; Female; Glucocorticoids; Humans; Indomethacin; Intraocular Pressure; Levofloxacin; Moxifloxacin; Ophthalmologic Surgical Procedures; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Pterygium; Scleritis; Vision Disorders; Visual Acuity | 2018 |
Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections.
Topics: Animals; Anti-Bacterial Agents; Cornea; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Humans; Keratitis; Mice; Mice, Inbred BALB C; Moxifloxacin; Ophthalmic Solutions; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Trimethoprim | 2019 |
Association between cytotoxic and invasive Pseudomonas aeruginosa and clinical outcomes in bacterial keratitis.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Toxins; Bacterial Typing Techniques; Corneal Ulcer; DNA, Bacterial; Exotoxins; Eye Infections, Bacterial; Fluoroquinolones; Genotype; Glucocorticoids; Humans; L-Lactate Dehydrogenase; Middle Aged; Moxifloxacin; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Virulence; Visual Acuity | 2013 |
RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria.
Topics: Anti-Bacterial Agents; Ceftazidime; Cells, Cultured; Ciprofloxacin; Daptomycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Guanidines; Humans; Microbial Sensitivity Tests; Monocytes; Moxifloxacin; Protein Synthesis Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Pyrimidinones; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2015 |
Microbiologic, Pharmacokinetic, and Clinical Effects of Corneal Collagen Cross-Linking on Experimentally Induced Pseudomonas Keratitis in Rabbits.
Topics: Animals; Anti-Bacterial Agents; Biological Availability; Collagen; Colony Count, Microbial; Cornea; Corneal Stroma; Corneal Ulcer; Cross-Linking Reagents; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Moxifloxacin; Photosensitizing Agents; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Riboflavin; Tissue Distribution | 2015 |
In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Ciprofloxacin; DNA Fingerprinting; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Synergism; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Microbial Viability; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Time Factors | 2008 |
Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Corneal Ulcer; Disease Models, Animal; Disease Susceptibility; DNA, Bacterial; Drug Resistance, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Sequence Analysis, DNA | 2011 |
Improvement in corneal scarring following bacterial keratitis.
Topics: Adult; Aged; Aza Compounds; Cicatrix; Corneal Ulcer; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Pneumococcal Infections; Prednisolone; Pseudomonas Infections; Quinolines; Vision Disorders; Visual Acuity | 2013 |
Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Colony Count, Microbial; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Half-Life; Microbial Sensitivity Tests; Moxifloxacin; Pneumococcal Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Regression Analysis; Streptococcus pneumoniae | 2003 |
Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation.
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Female; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Neutropenia; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Treatment Failure | 2004 |
Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Cornea; Eye Infections, Bacterial; Fluoroquinolones; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Serratia Infections; Serratia marcescens | 2004 |
Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Keratitis; Methicillin Resistance; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2005 |
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Opportunistic Infections; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Quinolones | 2005 |
Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery.
Topics: Adult; Aza Compounds; Bacteria; Cornea; Corneal Ulcer; Drug Resistance, Bacterial; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratomileusis, Laser In Situ; Keratoplasty, Penetrating; Lasers, Excimer; Microbial Sensitivity Tests; Moxifloxacin; Myopia; Photorefractive Keratectomy; Postoperative Complications; Pseudomonas Infections; Quinolines; Staphylococcal Infections | 2006 |
Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutagenicity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |